Loading company…
Oorja Bio develops therapies for cardiopulmonary and fibrotic diseases.
Oorja Bio is developing ORJ-001, a peptide therapy for idiopathic pulmonary fibrosis, and is focused on clinical-stage drug development. Founded in 2023 in Houston by Sujay Kango, Janethe Pena and Connie Coulomb, it raised USD 30 million in Series A funding in May 2026, led by Westlake village BioPartners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in